Faye C. Dannhauser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faye C. Dannhauser has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Juliet Alexandra Usher-Smith
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
2 shared publications Efthalia Massou
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
1 shared publication- Jo Waller
Wolfson Institute of Population Health, Queen Mary University of London, London, UK
1 shared publication Joanna S.L. Tung
Department of Public Health and Primary Care, University of Cambridge, Cambridge, England
1 shared publication- Lily C. Taylor
The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
1 shared publication - Rebecca Dennison
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (6) , 1-11
Evolving attitudes towards cancer screening: a 2024 update of UK population views
Background: This study assessed current population views about cancer screening in light of the Covid-19 pandemic, screening programme changes and new technological advances. Methods: UK adults (aged $$\ge$$ 18 years), recruited via the online platform, Prolific, completed a questionnaire about their views on cancer screening, using eight questions from a 2012 survey (weighted for age and sex, n = 603). We summarised participants’ views, explored associations with participant characteristics using logistic regression and compared 2024 and 2012 responses using Chi-square tests. Results: Public enthusiasm for cancer screening in the UK remained high with 93% believing routine screening is almost always beneficial, supported by strong beliefs that finding cancer early means treatment saves lives. Awareness of slow-growing cancers was modest at 51% but has increased since 2012. Nevertheless, most participants still wanted testing for slow-growing and untreatable cancer. Some believed they had received too few screening tests, particularly men, people from ethnic minority backgrounds and those with higher educational attainment. Conclusions: Our study showed that public appetite for screening persists even as awareness of slow-growing cancers increases, reflecting not only possible knowledge gaps but also trust, values and optimism about future treatments. Future research should explore these factors to support truly informed screening decisions.- 17 June 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (6) , 1-11
Open AccessEvolving attitudes towards cancer screening: a 2024 update of UK population views
Background: This study assessed current population views about cancer screening in light of the Covid-19 pandemic, screening programme changes and new technological advances. Methods: UK adults (aged $$\ge$$ 18 years), recruited via the online platform, Prolific, completed a questionnaire about their views on cancer screening, using eight questions from a 2012 survey (weighted for age and sex, n = 603). We summarised participants’ views, explored associations with participant characteristics using logistic regression and compared 2024 and 2012 responses using Chi-square tests. Results: Public enthusiasm for cancer screening in the UK remained high with 93% believing routine screening is almost always beneficial, supported by strong beliefs that finding cancer early means treatment saves lives. Awareness of slow-growing cancers was modest at 51% but has increased since 2012. Nevertheless, most participants still wanted testing for slow-growing and untreatable cancer. Some believed they had received too few screening tests, particularly men, people from ethnic minority backgrounds and those with higher educational attainment. Conclusions: Our study showed that public appetite for screening persists even as awareness of slow-growing cancers increases, reflecting not only possible knowledge gaps but also trust, values and optimism about future treatments. Future research should explore these factors to support truly informed screening decisions. - Open Access
- 21 May 2024
- Published by Springer Nature in Journal of Community Genetics
- Vol. 15 (3) , 217-234
The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
Background: Polygenic scores (PGS) have been developed for cancer risk-estimation and show potential as tools to prompt earlier referral for high-risk individuals and aid risk-stratification within cancer screening programmes. This review explores the potential for using PGS to identify individuals at risk of the most common cancers seen in primary care. Methods: Two electronic databases were searched up until November 2023 to identify quantitative, qualitative, and mixed methods studies that reported on the acceptability and clinical impact of using PGS to identify individuals at highest risk of breast, prostate, colorectal and lung cancer in primary care. The Mixed Methods Appraisal Tool (MMAT) was used to assess the quality of included studies and a narrative synthesis was used to analyse data. Results: A total of 190 papers were identified, 18 of which were eligible for inclusion. A cancer risk-assessment tool incorporating PGS was acceptable to the general practice population and their healthcare providers but major challenges to implementation were identified, including lack of evidence for PGS in non-European ancestry and a need for healthcare provider education in genomic medicine. A PGS cancer risk-assessment had relatively limited impact on psychosocial outcomes and health behaviours. However, for prostate cancer, potential applications for its use in primary care were shown. Conclusions: Cancer risk assessment incorporating PGS in primary care is acceptable to patients and healthcare providers but there is a paucity of research exploring clinical impact. Few studies were identified, and more research is required before clinical implementation of PGS can be recommended.
- 21 May 2024
- Published by Springer Nature in Journal of Community Genetics
- Vol. 15 (3) , 217-234
Open AccessThe acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
Background: Polygenic scores (PGS) have been developed for cancer risk-estimation and show potential as tools to prompt earlier referral for high-risk individuals and aid risk-stratification within cancer screening programmes. This review explores the potential for using PGS to identify individuals at risk of the most common cancers seen in primary care. Methods: Two electronic databases were searched up until November 2023 to identify quantitative, qualitative, and mixed methods studies that reported on the acceptability and clinical impact of using PGS to identify individuals at highest risk of breast, prostate, colorectal and lung cancer in primary care. The Mixed Methods Appraisal Tool (MMAT) was used to assess the quality of included studies and a narrative synthesis was used to analyse data. Results: A total of 190 papers were identified, 18 of which were eligible for inclusion. A cancer risk-assessment tool incorporating PGS was acceptable to the general practice population and their healthcare providers but major challenges to implementation were identified, including lack of evidence for PGS in non-European ancestry and a need for healthcare provider education in genomic medicine. A PGS cancer risk-assessment had relatively limited impact on psychosocial outcomes and health behaviours. However, for prostate cancer, potential applications for its use in primary care were shown. Conclusions: Cancer risk assessment incorporating PGS in primary care is acceptable to patients and healthcare providers but there is a paucity of research exploring clinical impact. Few studies were identified, and more research is required before clinical implementation of PGS can be recommended.